Rubicon Research Acquires US Manufacturing Facility for $2.9M

Rubicon Research Limited, through its wholly owned subsidiary AdvaGen Holdings Inc., has acquired a manufacturing facility in East Brunswick, New Jersey, USA, from InvaTech Pharma Solutions, LLC for an enterprise value of USD 2.9 million. The facility, which manufactures oral solid and oral liquid formulations, has a history of USFDA inspections. Rubicon plans to invest significantly over the next three years to expand its capabilities, focusing on specialty and high-value products, and expects to commence manufacturing in calendar year 2027. This acquisition marks Rubicon's first US manufacturing footprint, complementing its existing global operations and enhancing its supply chain resilience.